Skip to main content

Chronic Rhinosinusitis Without Nasal Polyps

1
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Paratek Pharmaceuticals
1 program
1
OPN-375Phase 31 trial
Active Trials
NCT06850805Recruiting84Est. Oct 2028
Regeneron
RegeneronTARRYTOWN, NY
2 programs
ItepekimabPHASE_2Monoclonal Antibody
Dupilumab SAR231893PHASE_3
SynDermix
SynDermixSwitzerland - Hunenberg
1 program
Vibration TherapyN/A1 trial
Active Trials
NCT04158596Withdrawn0Est. Oct 2021
Insmed
InsmedBRIDGEWATER, NJ
1 program
BrensocatibPHASE_21 trial
Active Trials
NCT06013241Completed288Est. Oct 2025
Sanofi
SanofiPARIS, France
1 program
Dupilumab SAR231893PHASE_31 trial
Active Trials
NCT04678856Completed71Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Paratek PharmaceuticalsOPN-375
InsmedBrensocatib
SanofiDupilumab SAR231893
SynDermixVibration Therapy

Clinical Trials (4)

Total enrollment: 443 patients across 4 trials

NCT06850805Paratek PharmaceuticalsOPN-375

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Start: Jul 2025Est. completion: Oct 202884 patients
Phase 3Recruiting
NCT06013241InsmedBrensocatib

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Start: Oct 2023Est. completion: Oct 2025288 patients
Phase 2Completed
NCT04678856SanofiDupilumab SAR231893

Dupilumab in CRSsNP

Start: Dec 2020Est. completion: Jan 202471 patients
Phase 2Completed
NCT04158596SynDermixVibration Therapy

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Start: Jun 2020Est. completion: Oct 20210
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 443 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.